Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Chemomab Therapeutics (CMMB) and Scipher Medicine to merge in $150m reverse deal
Scipher Medicine and Chemomab are merging in all-stock deal, taking Scipher public via reverse merger. $30M PIPE led by Northpond. Q4 2026 close, H1 2028 Phase 2 data.
Orchid Pharma (NSE: ORCHPHARMA) signs $178m Russia deal to commercialise Exblifep
Orchid Pharma signs a $178 million Russia deal for Exblifep. Read how the Pharmasyntez pact could reshape ORCHPHARMA’s global antibiotic strategy.
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps
Vera Therapeutics wins FDA approval for Trutakna as VERA stock jumps. Read how launch execution, pricing and full approval risks shape the next phase.
Otsuka’s Astex signs $490m-plus Genentech breast cancer partnership
Astex signs a $490 million-plus Genentech breast cancer deal. Discover how Otsuka’s fragment platform could reshape Roche oncology research and returns.
Vertex (VRTX) to enter endocrine diseases with $10bn Crinetics acquisition, targets $5bn peak revenue by 2029
Vertex Pharmaceuticals to acquire Crinetics for $10 billion at 102% premium, largest deal in VRTX history. Read the full analysis.
Novartis agrees $1.5bn Myricx Bio deal as ADC platform race intensifies
Novartis will pay $1.1 billion upfront for preclinical biotech Myricx Bio. Read why its novel ADC payload could reshape oncology strategy and NVS sentiment.
Ipsen agrees €700m Memo Therapeutics deal as acquisition spree accelerates
Ipsen agrees a €700 million Memo Therapeutics deal days after Kartos. Read how the acquisitions reshape its rare-disease pipeline and cash strategy now.
Bionyra raises $165m to build an immunology company from licensed assets
Bionyra launches with $165 million and three licensed immunology drugs. Read how its portfolio-first model could reshape biotech company creation.
HCLTech (NSE: HCLTECH) jumps 5.7% on $1.1bn AI deal before Q1 results
HCLTech won a US$1.14bn AI contract, yet FY27 growth guidance remains just 1% to 4%. July results must turn deal scale into earnings.